SCHEMBL31502346

SCHEMBL31502346

C#Cc1ccc(CC(=O)NC[C@@H](O)[C@@H](O)[C@@H]2O[C@@](OCc3ccccc3)(C(=O)O)C[C@H](O)[C@H]2NC(=O)CO)cc1

nearest known ligand 0.81

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CD22 P20273 13/20 0.81
▸ MAG P20916 3/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31502417 0.96 CD22 (0.83) CD22MAG
SCHEMBL31225764 0.95 CD22 (0.75) CD22MAG
SCHEMBL31225868 0.94 CD22 (0.74) CD22MAG
SCHEMBL31502390 0.92 CD22 (0.77) CD22MAG
SCHEMBL31502522 0.89 CD22 (0.76) CD22MAG
SCHEMBL31502407 0.89 CD22 (0.71) CD22MAG
SCHEMBL31502472 0.88 CD22 (0.72) CD22MAG
SCHEMBL31225671 0.88 CD22 (0.79) CD22MAG
SCHEMBL31502520 0.88 CD22 (0.72) CD22MAG
SCHEMBL31502333 0.88 CD22 (0.66) CD22MAG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127904-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-04-24 — — US disclosed
WO-2025076427-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2025-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127904-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF SIGLEC7, SIGLEC9, SELPLG CD22 8/4885MAG 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback